Patents by Inventor Stephen Logarnini

Stephen Logarnini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
    Patent number: 8367317
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: February 5, 2013
    Assignee: Melbourne Health; St. Vincent's Hospital Melbourne; Austin Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Logarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • VARIANTS OF HEPATITIS B VIRUS WITH RESISTANCE TO ANTI-VIRAL NUCLEOSIDE AGENTS AND APPLICATIONS THEREOF
    Publication number: 20110236422
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: December 23, 2010
    Publication date: September 29, 2011
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Logarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus